The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NEOSPACE trial: Neoadjuvant pembrolizumab-gemcitabine-cisplatin followed by concurrent pembrolizumab-chemoradiation and maintenance pembrolizumab for stage IVA nasopharyngeal cancer (NPC).
 
Edwin P Hui
Honoraria - Merck
Research Funding - MSD Oncology (Inst); Pfizer/EMD Serono (Inst)
 
Brigette Ma
Honoraria - BeiGene; Merck Serono; Merck Sharp & Dohme
Consulting or Advisory Role - Alentis Therapeutics; Merck Sharp & Dohme; Novartis; Viracta Therapeutics; Y-biologics
Research Funding - Boehringer Ingelheim; Merck Serono; Novartis
Travel, Accommodations, Expenses - Merck Serono
 
Darren Wan-Teck Lim
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD Oncology; Novartis; Roche
Research Funding - Bristol-Myers Squibb (Inst)
 
WK Jacky Lam
Stock and Other Ownership Interests - GRAIL
Patents, Royalties, Other Intellectual Property - I hold multiple patents on the use of circulating nucleic acids for diagnostics.
 
Yoke Lim Soong
Stock and Other Ownership Interests - GlaxoSmithKline (I)
 
Leung Li
No Relationships to Disclose
 
Kenneth C.W. Wong
Travel, Accommodations, Expenses - Ipsen; Roche
 
Daisy Lam
No Relationships to Disclose
 
Florence Mok
No Relationships to Disclose
 
Macy Tong
No Relationships to Disclose
 
Darren MC Poon
No Relationships to Disclose
 
Chi Hang Wong
No Relationships to Disclose
 
Frankie Mo
No Relationships to Disclose
 
Ann Dorothy King
No Relationships to Disclose
 
Kwok-Wai Lo
Research Funding - ScinnoHub Pharmaceutical (Inst); Viracta Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - US Patent no.:10,421,968B2 (Inst); US Patent no.:US9,464,327B2 (Inst); US Provisional Patent Application No.: 63/267,737 (Inst); WO 2021/173977A9; PCT/US2021/019880 (Inst)
 
Jason Y.K. Chan
Leadership - Agilis Robotics
Stock and Other Ownership Interests - Agilis Robotics; Talem Medical Group
Honoraria - Intuitive Surgical
Consulting or Advisory Role - Aptorum
Research Funding - Merck; Signate Life Sciences (Hong Kong) Ltd
Patents, Royalties, Other Intellectual Property - Patents pending on image guided surgery
 
KC Allen Chan
Stock and Other Ownership Interests - Grail; Illumina; Take2 Health
Research Funding - Grail
Patents, Royalties, Other Intellectual Property - I have patent portfolios licensed to Grail, Illumina, Take2, DRA and Xcelom. I receive royalties from these companies.
 
Anthony T. C. Chan
Stock and Other Ownership Interests - CSPC Pharmaceutical Group (I); WuXi Biologics (I)
Honoraria - Merck Sharp & Dohme; Tessa Therapeutics
Consulting or Advisory Role - Merck Sharp & Dohme; Tessa Therapeutics
Research Funding - Merck Sharp & Dohme; Novartis; Pfizer
Travel, Accommodations, Expenses - Roche